Primary Focal Segmental Glomerulosclerosis
Information
- Disease name
- Primary Focal Segmental Glomerulosclerosis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04983888 | Active, not recruiting | Phase 2 | Obinutuzumab in Primary FSGS | November 17, 2021 | September 2025 |
| NCT01573533 | Completed | Phase 2 | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS | October 2013 | November 15, 2018 |
| NCT01665391 | Completed | Phase 2 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | August 2012 | November 2014 |
| NCT03422510 | Completed | Phase 2 | FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) | April 15, 2018 | July 31, 2020 |
| NCT06315504 | Not yet recruiting | Circulating Factors in Nephrotic Syndrome | April 1, 2024 | April 1, 2034 |
- MedGen concept unique identifier (MedGen Concept name)
- C1709661
- MedGen unique identifier (MedGen Concept name)
- 313617